Michael Andrew Singer

Principal Investigator

January 2003 – July 2005 A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope (IMT) in Patients with Central Vision Impairment Associated with Age Related Macular Degeneration of Stargardt's Macular Dystrophy – Sub-Investigator

May 2003 – December 2005 A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration - Principal Investigator

August 2003 – February 2006 A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment–Controlled Study of the Efficacy and Safety of rhuFab V2 (ranibizumab) Compared to Verteporfin (Visudyne) Photodynamic Therapy in Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration – Principal Investigator

April 2004 – Present A Randomized, Single-masked, Multi-center, Phase 2 Evaluation of the Effect of Photodynamic Therapy Using Verteporfin (Visudyne Therapy) In Combination with Intravitreal Injection of Either 0 mg, 1 mg, or 4 mg of Triamcinolone Acetonide in Occult Subfoveal and Minimally Classic Subfoveal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) – Principal Investigator

April 2004 – September 2005 A Phase II Prospective, Randomized, Double Masked, Sham-contolled, Dose Ranging, Multi-center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative, Subfoveal, Age-Related Macular Degeneration (AMD) -- Principal Investigator

April 2004 – Present A Six Month Phase 3, Multi-center, Masked, Randomized, Sham-controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficcy of 700 µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS Applicator System) in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion -- Principal Investigator

January 2005 – Present A 3 year, Phase III, Multi-Center, Masked, Randomized, Sham-Controlled Trial to Assess the Safety and Efficacy of 700µg and 350 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Diabetic Macular Edema—Principal Investigator

June 2005 – Present An Open-label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of a Genentech-Sponsored Ranibizumab Study—Principal Investigator

November 2005 – Present A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Toloerability of Ranibzumab in Naive and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) – Principal Investigator       

Now FDA approved

LUCENTIS (ranibizumab injection) is a prescription medicine for the treatment of patients with wet age-related macular degeneration (AMD). LUCENTIS has been shown to maintain or improve vision in wet AMD. For more information, please contact our office or log onto www.lucentis.com.

Awards

September 2006 - ASRS (American Society of Retina Specialists)

                                 Honor Award
Physician Innovation Award
Kaiser Permanente 1994

Publications and Presentations

Singer, M.A.; Wong, E.; Yaplee, S.,
The Presentation of a Lost Contact Lens, (Letter)
CLAO, 1986 Oct-Dec (4) p. 200-201, presented
At CLAO meeting, 1986 (poster), Las Vegas, Nevada

Gaster, R.; Burstein, N.; Singer, MA
Laser Surgery of the Cornea. Investigative
Ophthalmology and Visual Sciences; 1987 (14);
45 Presented as a paper
ARVO 1987, Sarasota, Florida

Singer, MA; Schwatz, S.D.;
Green, R.L.; Cano, M.; Barlow, W.E.;
Ligget, P.E.; Ryan, S.J.,
Factors Associated with Retinal Detachment in
Penetrating Ocular Trauma. Investigative
Science; 1988 (29) : 303 Presented as a poster
ARVO 1988, Sarasota, Florida

Singer, MA; Warren, F.; Accardi, F.;
D'amico, R., Gastric Adenocarcinoma
Metastatic to the Orbit in the IV Patient.
Presented at the New York Academy of
Medicine May 1989. Amer. Journal of Ophth
Vol 110 (Issue No. 6) Dec, 1990, pg 707-709

Singer, MA; Torres, R.; Wecker, J.;
Moscoso, W.; Dahms, M.: Long, R.S.; D'Amico, R.
A Prospective Study of Retinopathy on HIV
Positive Patients: Investigative
Ophthalmology and Visual Science;
1990 (31): 142. Presented as a poster at
ARVO 1990, Sarasota, Florida. Retina Society
Meeting October 5, 1990, and as a poster
American Academy of Ophthalmology Meeting
October 28-November 3, 1990.

Singer, MA; Hagler, WS;
Grosniklaus, H.E.; Toxoplasmosa Gondii
Retinochoroiditis after Liver Transplantation
Retina Vol 13 (Issue No 1) pg 40-45, 1993

Singer, MA; Rao, N; The Pathologic Effects of
Retina Perflourocarbons
Presented at the Vitreous Society
August 1994
Submitted for Publication

Singer, MA; Kowalski, G; The use of EMLA to
Reduce Pain of Botulinum Toxin Injections,
Presented a Blepharospasm Conference
September 1995

Singer, MA; Botulinum Toxin Treatment of Essential
Blepharospasm and Hermifacial spasm.
Ophthalmology Vol 3, 3 pg 48, September 1996.

Licensure

Texas State License, #J8373
Georgia State License, #34244
New York State License, #175203
Colorado State License, #28717
California State License, #G060590